Literature DB >> 32052578

Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasion.

Jinbo Chen1,2, Yin Sun2, Zhenyu Ou1, Shuyuan Yeh2, Chi-Ping Huang3, Bosen You2, Yu-Chieh Tsai2, Tzong-Jen Sheu4, Xiongbing Zu1, Chawnshang Chang2,3.   

Abstract

The androgen receptor (AR) has been linked to bladder cancer (BCa) progression, but if this involves circular RNAs (circRNAs) remains unclear. Here, we find that AR alters the levels of circRNA-FNTA (circFNTA) to increase BCa cell invasion and chemo-resistance. Mechanistically, AR represses the RNA editing gene ADAR2 via direct binding to its 5' promoter region to increase circFNTA levels, which then sponges the microRNA miR-370-3p to increase the expression of its host gene FNTA. This AR-mediated ADAR2/circFNTA/miR-370-3p/FNTA pathway then activates KRAS signaling to alter BCa cell invasion and chemo-sensitivity to cisplatin. A clinical BCa sample survey shows that circFNTA expression is elevated in BCa tissues, and results from a BCa mouse model indicate that depletion of circFNTA leads to the suppression of BCa metastases and increased cisplatin chemo-sensitivity. Together, based on our results using multiple BCa cell lines and an in vivo mouse model we suggest that targeting this newly identified AR/ADAR2/circFNTA/miR-370-3p/FNTA/KRAS axis may lead to the development of therapies to suppress BCa metastasis and to increase its chemo-sensitivity.
© 2020 The Authors.

Entities:  

Keywords:  bladder cancer; chemo-sensitivity; circular RNA

Mesh:

Substances:

Year:  2020        PMID: 32052578      PMCID: PMC7132336          DOI: 10.15252/embr.201948467

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  41 in total

Review 1.  KRAS as a Therapeutic Target.

Authors:  Frank McCormick
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

Review 2.  Circular RNAs (circRNAs) in cancer.

Authors:  Ruoyu Zhou; Yuwei Wu; Wenxi Wang; Wenjia Su; Yicong Liu; Yumin Wang; Chunmei Fan; Xiaoling Li; Guiyuan Li; Yong Li; Wei Xiong; Zhaoyang Zeng
Journal:  Cancer Lett       Date:  2018-04-03       Impact factor: 8.679

Review 3.  Circular RNA: A new star of noncoding RNAs.

Authors:  Shibin Qu; Xisheng Yang; Xiaolei Li; Jianlin Wang; Yuan Gao; Runze Shang; Wei Sun; Kefeng Dou; Haimin Li
Journal:  Cancer Lett       Date:  2015-06-05       Impact factor: 8.679

4.  DHX9 suppresses RNA processing defects originating from the Alu invasion of the human genome.

Authors:  Tuğçe Aktaş; İbrahim Avşar Ilık; Daniel Maticzka; Vivek Bhardwaj; Cecilia Pessoa Rodrigues; Gerhard Mittler; Thomas Manke; Rolf Backofen; Asifa Akhtar
Journal:  Nature       Date:  2017-03-29       Impact factor: 49.962

5.  Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.

Authors:  Keiran S M Smalley; Tim G Eisen
Journal:  Int J Cancer       Date:  2003-06-10       Impact factor: 7.396

6.  Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.

Authors:  Meng Liu; Anna-Karin M Sjogren; Christin Karlsson; Mohamed X Ibrahim; Karin M E Andersson; Frida J Olofsson; Annika M Wahlstrom; Martin Dalin; Huiming Yu; Zhenggang Chen; Shao H Yang; Stephen G Young; Martin O Bergo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

Review 7.  Bladder cancer.

Authors:  Ashish M Kamat; Noah M Hahn; Jason A Efstathiou; Seth P Lerner; Per-Uno Malmström; Woonyoung Choi; Charles C Guo; Yair Lotan; Wassim Kassouf
Journal:  Lancet       Date:  2016-06-23       Impact factor: 79.321

Review 8.  Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver.

Authors:  C Chang; S O Lee; S Yeh; T M Chang
Journal:  Oncogene       Date:  2013-07-22       Impact factor: 9.867

9.  Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway.

Authors:  Zhenyu Zhong; Mengge Huang; Mengxin Lv; Yunfeng He; Changzhu Duan; Luyu Zhang; Junxia Chen
Journal:  Cancer Lett       Date:  2017-07-04       Impact factor: 8.679

10.  A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.

Authors:  Ning Ding; Xiao-Xing Cui; Zhi Gao; Huarong Huang; Xingchuan Wei; Zhiyun Du; Yong Lin; Weichung Joe Shih; Arnold B Rabson; Allan H Conney; Chunhong Hu; Xi Zheng
Journal:  Int J Oncol       Date:  2014-03-19       Impact factor: 5.650

View more
  27 in total

1.  Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling.

Authors:  Qing Liu; Bosen You; Jialin Meng; Chi-Ping Huang; Guanglu Dong; Ronghao Wang; Fuju Chou; Shan Gao; Chawnshang Chang; Shuyuan Yeh; Wanhai Xu
Journal:  Cancer Gene Ther       Date:  2022-08-01       Impact factor: 5.854

2.  Identifying common transcriptome signatures of cancer by interpreting deep learning models.

Authors:  Anupama Jha; Mathieu Quesnel-Vallières; David Wang; Andrei Thomas-Tikhonenko; Kristen W Lynch; Yoseph Barash
Journal:  Genome Biol       Date:  2022-05-17       Impact factor: 17.906

Review 3.  Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives.

Authors:  Sen Liu; Xu Chen; Tianxin Lin
Journal:  J Adv Res       Date:  2021-11-24       Impact factor: 12.822

4.  Aloperine Exerts Antitumor Effects on Bladder Cancer in vitro.

Authors:  Lijun Zhang; Jun Liang; Xiaohua Liu; Jianhua Wu; Daqing Tan; Wei Hu
Journal:  Onco Targets Ther       Date:  2020-10-13       Impact factor: 4.147

5.  Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasion.

Authors:  Jinbo Chen; Yin Sun; Zhenyu Ou; Shuyuan Yeh; Chi-Ping Huang; Bosen You; Yu-Chieh Tsai; Tzong-Jen Sheu; Xiongbing Zu; Chawnshang Chang
Journal:  EMBO Rep       Date:  2020-02-13       Impact factor: 8.807

6.  Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis.

Authors:  Kimberley Katleba; Alan P Lombard; Maria-Malvina Tsamouri; Han Bit Baek; Kristine S Nishida; Stephen J Libertini; Alexander J Platero; Ai-Hong Ma; Chong-Xian Pan; Paramita M Ghosh; Maria Mudryj
Journal:  Cancer Lett       Date:  2021-02-04       Impact factor: 8.679

Review 7.  Functions of circular RNAs in bladder, prostate and renal cell cancer (Review).

Authors:  Longfei Yang; Xiaofeng Zou; Junrong Zou; Guoxi Zhang
Journal:  Mol Med Rep       Date:  2021-03-02       Impact factor: 2.952

Review 8.  CircRNAs: Emerging Bladder Cancer Biomarkers and Targets.

Authors:  Zhaofeng Liang; Wenhao Guo; Shikun Fang; Yue Zhang; Ling Lu; Wenrong Xu; Hui Qian
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

Review 9.  The Biogenesis, Functions, and Roles of circRNAs in Bladder Cancer.

Authors:  Changjiu Li; Xian Fu; Huadong He; Chao Chen; Yuyong Wang; Lugeng He
Journal:  Cancer Manag Res       Date:  2020-05-19       Impact factor: 3.989

Review 10.  CircRNAs in anticancer drug resistance: recent advances and future potential.

Authors:  Tianwei Xu; Mengwei Wang; Lihua Jiang; Li Ma; Li Wan; Qinnan Chen; Chenchen Wei; Zhaoxia Wang
Journal:  Mol Cancer       Date:  2020-08-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.